Erratum: Corrigendum to ‘Impact of antiretroviral therapy on bone metabolism markers in HIV-seropositive patients” (Bone (2013) 57 (62–67) (S8756328213002810) (10.1016/j.bone.2013.07.019));Impact of antiretroviral therapy on bone metabolism markers in HIV-seropositive patients

Bone

Volumn 57, Issue 1, 2013, Pages 62-67

  de Menezes Barbosa, Erika Grasiela Marques ^a   de Paula, Francisco Jose Albuquerque ^b   Machado, Alcyone Artioli ^b   de Assis Pereira, Francisco ^b   Barbosa, Fernando ^b   Navarro, Anderson Marliere ^b  

^a FMRP USP ^*  (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

ART; Bone metabolism; HIV; Osteopenia; Osteoporosis

Indexed keywords

25 HYDROXYVITAMIN D; ALBUMIN; CALCIUM; CREATININE; DEOXYPYRIDINOLINE; FOLLITROPIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LUTEINIZING HORMONE; MAGNESIUM; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHORUS; RNA DIRECTED DNA POLYMERASE INHIBITOR; SOMATOMEDIN C; TESTOSTERONE; UREA;

ADULT; AGE; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; BODY WEIGHT; BONE DENSITY; BONE METABOLISM; CALCIUM INTAKE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUMBAR SPINE; MALE; MINERAL METABOLISM; OSTEOPENIA; OSTEOPOROSIS; PROTEIN INTAKE; VIREMIA; VITAMIN D DEFICIENCY;

ART; BONE METABOLISM; HIV; OSTEOPENIA; OSTEOPOROSIS;

ABSORPTIOMETRY, PHOTON; ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY COMPOSITION; BONE DENSITY; BONE DISEASES, METABOLIC; CALCIUM; CROSS-SECTIONAL STUDIES; HIV INFECTIONS; HUMANS; MALE; OSTEOPOROSIS; YOUNG ADULT;

EID: 84882751750     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2016.06.002     Document Type: Erratum

References (39)

1. Focà E., Motta D., Borderi M., Gottii D., Albini L., Calabresi A., et al. Prospective evaluation of bone markers, parathormone and 1,25-(OH)2 vitamin D in HIV positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz. BMC Infect Dis 2012, 12:38.
2. Zuccotti G., Vigano A., Gabiano C., Giacomet V., Mignone F., Stucchi S., et al. Antiretroviral therapy and bone mineral measurements in HIV-infected youths. Bone 2010, 46:1633-1638.
3. Cournil A., Eymard-Duvernay S., Diouf A., Moquet C., Coutherut J., Ngom Gueye N.F., et al. Reduced quantitative ultrasound bone mineral density in HIV-infected patients on antiretroviral therapy in Senegal. PLoS One 2012, 7. 10.1371/journal.pone.0031726.
4. Deeks S.G. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2011, 62:141-155.
5. Deeks S.G. Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med 2009, 17:118-123.
6. Capeau J. Premature aging in human immunodeficiency virus (HIV) infected patients: detection, pathophysiological mechanisms and management. Bull Acad Natl Med 2011, 195:2013-2022.
7. Haskelberg H., Carr A., Emery S. Bone turnover markers in HIV disease. AIDS Ver 2011, 13:240-250.
8. Borderi M., Gibellini D., Vescini F., Crignis E., Cimatti L., Biagetti C., et al. Metabolic bone disease in HIV infection. AIDS 2009, 23:1297-1310.
9. Stone B., Dockrell D., Bowman C., McCloskey E. HIV and bone disease. Arch Biochem Biophys 2010, 503:66-77.
10. Czepiel J., Biesiada G., Mach T., Garlicki A. Osteopenia and osteoporosis among patients with human immunodeficiency virus infection. HIV AIDS Rev 2012, 11:37-41.
11. Mccomsey G., Kitch D., Daar E., Tiemey C., Jahed N., Tebas P., et al. Bone and limb fat outcomes of ACTG A5224s, a substudy of ACTG A5202: a prospective, randomized, partially blinded phase III trial of ABC/3TC or TDF/FTC with EFV or ATV/r for initial treatment of HIV-1 infection. 17th Conference on Retroviruses and Opportunistic infections, 2010, San Francisco, USA March 10 2012, [Disponível em:< http://www.natap.org/2010/CROI/croi_20.htm].
12. Grigsby I.F.P.L., Mansky L.M., Gopalakrishnan R., Carlson A.E., Mansky K.C. Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss. Biochem Biophys Res Commun 2010, 394:48-53.
13. Rosen C.J., Gallagher J.C. The 2011 IOM report on vitamin d and calcium requirements for North America: clinical implications for providers treating patients with low bone mineral density. J Clin Densitom Assess Skelet Health 2012, 14:79-84.
14. Hoppe E., Morel G., Biver E., Borg S., Chopin F., Legrand E. Male osteoporosis: do sex steroids really benefit bone health in men?. Joint Bone Spine 2011, 78:S191-S196.
15. Lin W.P., Lin J. Parathyroid hormone for osteoporosis treatment. Formosan J Musculoskelet Disord 2011, 2:113-117.
16. Brown T.T., Mccomsey G.A., King M.S., Qaqish R.B., Bernstein B.M., Da Silva B.A. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009, 51:554-561.
17. Horizon A.A., Joseph R.J., Liao Q., Ross S.T., Pakes G.E. Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy. HIV AIDS (Auckl) 2011, 3:53-59.
18. Rivas P., Górgolas M., García D.R., Díaz C.M., Goyenechea A., Fernández G.M.L. Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir. HIV Med 2008, 9:89-95.
19. WHO - World Health Organization BMI classification Disponível em:. http://apps.who.int/bmi/.
20. TACO - Table Brasileira De Composição De Alimentos 4a. edição revisada e ampliada Disponível em:. http://www.unicamp.br/nepa/taco/Table/.
21. Thompson F.E., Byers T. Dietary assessment resource manual. J Nutr 1994, 124:2245S-2317S.
22. SAS Institute Inc. SAS/STAT® user's guide, version 9.2 2002, SAS Institute Inc., Cary, NC.
23. R Development Core Team R: a language and environment for statistical computing 2009, R. Foundation for Statistical Computing, Vienna, Austria, [ISBN 3-9000051-07-0].
24. Arnsten J.H., Freeman R., Howard A.A., Moore M.F., Lo Y., Kleina R.S. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS 2007, 21:617-623.
25. Womack J.A., Goulet J.L., Gibert C., Brandt C., Chang C.C., Gulanski B., et al. Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One 2011, 6. 10.1111/j.1530-0277.2011.01601.x.
26. Ofotokun I., Weitzamnnn M.N. HIV and bone metabolism. Discov Med 2011, 11:385-393.
27. Haskelberg H., Hoy J.F., Amin J., Ebeling P.R., Emery S., Carr A., et al. Changes in bone turnover and bone loss in HIV infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine. PLoS One 2012, 7:1-9.
28. Haskelberg H., Carr A., Emery S. Bone turnover markers in HIV disease. AIDS Ver 2011, 13:240-250.
29. Chung M., Balk E.M., Brendel M., Ip S., Lau J., Lee J., et al. Vitamin D and calcium: a systematic review of health outcomes. Evid Rep Technol 2009, 183:1-420.
30. Szejnfeld V.L. Composição e organização do osso (cap 1). Remodelação óssea (cap. 2). Homeostasia mineral (cap. 3). Regulação hormonal do metabolismo mineral (cap. 4). Osteoporose - diagnóstico e tratamento 2000, 3-39. Sarvier, São Paulo.
31. Emkey R.D., Emkey G.R. Calcium metabolism and correcting calcium deficiencies. Endocrinol Metab Clin North Am 2012, 41:527-556.
32. Grunda B., Penga G., Gibertb C.L., Hoyc J.F., Isakssona R.L., Shlayd J.C., et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS 2009, 23:1519-1529.
33. Eysteinsdottir T., Thorsdottir I., Gunnarsdottir I., Steingrimsdottir L. Assessing validity of a short food frequency questionnaire on present dietary intake of elderly Icelanders. Nutr J 2012, 11:12.
34. WHO - World Health Organization Assessment of fracture risk and its application to screening for postmenopausal osteoporosis (WHO Technical Report Series, No. 843) Geneva 1994.
35. DIET PRO, VERSÃO 5.i. Software de avaliação nutricional e prescrição dietética. UFV. Viçosa, MG, Brasil. A. S. Sistema 1997.
36. BRASIL. MINISTÉRIO DA SAÚDE - Contagem de células T CD4+ e testes de carga viral: principais marcadores laboratoriais para indicação e monitorização ao tratamento anti-retroviral Available at:. http://bvsms.saude.gov.br/bvs/publicacoes/16contagem_celulasTCDA.pdf.
37. Holick M.F. Vitamin D, deficiency. N Engl J Med 2007, 357:266-281.
38. Young D.S. Implementation of SI units for clinical laboratory data. Annals Intern Med 1987, 106:114-129.
39. Aaseth J., Boivin G., Andersen O. Osteoporosis and trace elements. J Trace Elem Med Biol 2012, 26:149-152.